Session Information
Date: Thursday, June 8, 2017
Session Title: Parkinson's Disease: Neuroimaging And Neurophysiology
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson’s disease (PD).
Background: 18F-DOPA positron emission tomography (PET) is considered the ‘gold standard’ for measuring the integrity of dopaminergic function in PD. However, 18F-DOPA metabolism in non-dopaminergic neurons and disease-related compensatory upregulation of amino acid decarboxylase (AADC) may result in underestimation of dopamine cell loss.
Methods: Thirty-three mild-moderate PD patients underwent PET at baseline (Age=55.1±7.0; Duration=5.9±2.2); twenty-three were followed-up at 19.4±3.3m (Age=56.8±7.1; Duration=7.2±2.0). Striatal 18F-DOPA Ki and 11C-PE2I BPND were quantified using Patlak graphical method (t*=30) and simplified reference tissue model respectively, with cerebellar reference.
Results: Standard multiple regression at baseline indicated that 11C-PE2I BPND significantly predicted total UPDRS-III (β=-0.474, p<0.05) and bradykinesia scores (β=-0.610, p<0.01), whereas 18F-DOPA Ki did not significantly contribute to either model. Voxel-wise analysis revealed large clusters showing negative correlation between 11C-PE2I BPND and motor severity extending across putamen, caudate and ventral striatum bilaterally. 18F-DOPA Ki voxel-wise analysis revealed smaller clusters restricted to most affected putamen and caudate. Longitudinally, significant negative correlations were found between striatal Δ11C-PE2I BPND, ΔUPDRS-III [rs(21)=-0.43, p=0.040] and Δbradykinesia [rs(21)=-0.44, p=0.035]. No associations were found between Δ18F-DOPA Ki, ΔUPDRS-III [rs(21)=-0.053, p=0.81] and Δbradykinesia [rs(21)=0.026, p=0.91].
Conclusions: Results suggest striatal DAT is more closely associated with clinical severity and rate of disease progression than AADC and 18F-DOPA-derived measures of striatal dopamine storage capacity. 11C-PE2I PET may be useful for objectively evaluating efficacy of neuroprotective treatments in PD.
To cite this abstract in AMA style:
W. Li, N. Lao-Kaim, A.-A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R. Barker, P. Piccini. Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/longitudinal-comparison-of-11c-pe2i-and-18f-dopa-pet-for-assessing-severity-and-rate-of-disease-progression-in-patients-with-parkinsons-disease/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-comparison-of-11c-pe2i-and-18f-dopa-pet-for-assessing-severity-and-rate-of-disease-progression-in-patients-with-parkinsons-disease/